Early therapeutic drug monitoring helps to identify inflammatory bowel disease patients with a high risk to fail thiopurine treatment
Thiopurine metabolite concentrations at T1 were related to early treatment discontinuation and skewed metabolism at steady state, but not to effectiveness, helping to identify patients with a high risk of thiopurine treatment failure.
Authors
- Nanne K.H. de Boer (ORCID: https://orcid.org/0000-0001-8357-9887)
- Adriaan A. van Bodegraven
- Marieke J. Pierik (ORCID: https://orcid.org/0000-0001-6981-6516)
- Paul Bus
- Debbie S. Deben (ORCID: https://orcid.org/0000-0002-2956-5713)
- Sofia A. W. van Moorsel
- B.P.C. van Oijen
- Mathie P.G. Leers (ORCID: https://orcid.org/0000-0001-5186-5600)
- Dennis R. Wong (ORCID: https://orcid.org/0000-0002-3835-2613)
- Melek Simsek (ORCID: https://orcid.org/0000-0001-8827-955X)
- Björn Winkens (ORCID: https://orcid.org/0000-0002-6747-6228)
Institutions
- Maastricht University (NL)
- Zuyderland Medisch Centrum (NL)
- Amsterdam University Medical Centers (NL)
- Laurentius Ziekenhuis (NL)
- Ziekenhuis Bernhoven (NL)
- Jeroen Bosch Ziekenhuis (NL)
- Open University of the Netherlands (NL)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2024-08-25
- DOI
- https://doi.org/10.1111/bcp.16219
- Citations
- 2
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 1.09